In an interim analysis of a Phase 3 trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir was found to have cut the risk of hospitalization or death by 50%.
Best part is: It's a pill... (no hospital visit to get Uncle Leo's magic anti-everything Elixer injected into you... )
As usual... IPIX isn't even dressed with shoes on as the game winds down.
It's dropping because there's other therapeutics hitting the market soon... Unless Leo gets emergency use data will not matter... A phase 3 is not in-the-cards... Been saying this for a year... The costs and time to complete would not be worth the revenue potential which is a big fat DON'T KNOW or HAVE a CLUE...